Verve Therapeutics
Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, is developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company's lead programs – VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high low-density lipoprotein cholesterol levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high low-density lipoprotein cholesterol despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce lipoprotein (a) levels. Lipoprotein (a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis.
7-day free trial · no credit card
Verified contacts
168
available on Kipplo
LinkedIn employees
185
201 to 500 range
Open roles
2
across 1 depts
Distinct roles
119
indexed titles
Tech stack
2
tools in use
Monthly traffic
1.7K
organic / mo
Hiring · 2 open positions across 1 departments
Sign up free to see all 168 verified contacts at Verve Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
168 contacts with verified email or phone · masked until revealed.
- AK
Allen K. Barrett
Director, Corporate Counsel · Legal
EmailPhone - AD
Ann Dougherty
Senior Director, Medical Writing · Writing/Editing
EmailPhone - CR
Caroline Reiss
Associate Director, Rna Technology & Engineering · Other
EmailPhone - ER
Ellen Rohde
Head Preclinical Development · Research & Development
EmailPhone - EB
Erin Brady
Associate Director Clinical Operations · Operations
EmailPhone - EG
Erin Garrity
Senior Director, Corporate Counsel · Legal
EmailPhone - FC
Florence Chan
Director, Human Resources Business Partner · Human Resources
EmailPhone - JD
Jamie Denizio
Associate Director · Research & Development
EmailPhone - JW
Jill Wilson
Director, Hrbp · Human Resources
EmailPhone
Showing 9 of 168 verified contacts
Top roles at Verve Therapeutics
119 distinct titles indexed · top 10 shown.
- 3()
- 3associate scientist
- 3director
- 3scientist
- 3senior research associate
- 2' -
- 2,,
- 2associate director
- 2associate director, clinical data management
- 2principal scientist
- +109more titles
Sign up to unlock all 168 contacts at Verve Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 168 verified contacts at Verve Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.